Leading BioSciences, Inc. (LBS), a development stage pharmaceutical company focused on novel treatments in the critical care of acute shock and Multiple Organ Failure (MOF), announced that In a release, the Company said that Dr. Jackman succeeds Dr.
"Leading BioSciences is advancing a revolutionary platform whose initial focus is the treatment and prevention of Multiple Organ Failure, a condition most commonly associated with severe sepsis," said Dr. Flaim. "We are delighted that Dr. Jackman has joined Leading BioSciences with his proven and successful track record as an early-stage biotech executive. With the additions of both Robin and Tom, we have the right team to advance our lead therapeutic LB1148 into Phase 2 clinical studies both nationally and internationally."
A 20-year biopharmaceutical industry veteran, LBS said that Robin was most recently President and CEO of
"Leading BioSciences is developing a remarkable platform with novel and fundamental insights into the underlying mechanisms of several serious conditions," said Dr. Jackman. With the promise of our early clinical data, I am looking forward to advancing our treatment for MOF into an efficacy study in these critically ill patients with severe sepsis and septic shock."
LBS also recently expanded its management team with the addition of Dr.
LBS said that Dr. Hallam previously served as the Director of Therapeutic Programs and New Product Development Head for
"The addition of Dr. Hallam is a critical advancement in the company's ability to manage and progress the clinical and regulatory efforts of LB1148," said Dr. Flaim. "Dr. Hallam's experience with the
((Comments on this story may be sent to email@example.com))
Leading BioSciences, Inc. (LBS), a development stage pharmaceutical company focused on novel treatments in the critical care of acute shock and Multiple Organ Failure (MOF), announced that
In a release, the Company said that Dr. Jackman succeeds Dr.